摘要
作为一种重要的转录后修饰,组蛋白去乙酰化在染色质重塑和基因表达中起着重要作用。 组蛋白去乙酰化的异常修饰会导致各种疾病。 作为组蛋白去乙酰化酶 (HDAC) 的关键成员,HDAC6 在许多生理过程中充当关键调节剂。 HDAC6 的异常表达会导致癌症、神经变性和其他疾病。 在这里,我们回顾了 HDAC6 选择性抑制剂的生理学、蛋白质结构和开发方面的最新进展。
关键词: 转录后修饰,HDAC6,结构,癌症,选择性抑制剂,组蛋白去乙酰化。
Current Medicinal Chemistry
Title:Recent Development of Novel HDAC6 Isoform-selective Inhibitors
Volume: 28 Issue: 21
关键词: 转录后修饰,HDAC6,结构,癌症,选择性抑制剂,组蛋白去乙酰化。
摘要: As an important post-transcription modification, histone deacetylation plays significant roles in chromatin remodeling and gene expression. The aberrant modification of histone deacetylation leads to various diseases. As a critical member of histone deacetylase (HDAC), HDAC6 serves as a key modulator in many physiological processes. Abnormal expression of HDAC6 gives rise to cancer, neurodegeneration and other diseases. Here, we have reviewed recent advances in physiological, protein structure and development of HDAC6 selective inhibitors.
Export Options
About this article
Cite this article as:
Recent Development of Novel HDAC6 Isoform-selective Inhibitors, Current Medicinal Chemistry 2021; 28 (21) . https://dx.doi.org/10.2174/0929867327666201111142653
DOI https://dx.doi.org/10.2174/0929867327666201111142653 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
TGF-beta Signaling in Cancer Treatment
Current Pharmaceutical Design Novel Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia
Current Cancer Drug Targets Latest Insights into the Anticancer Activity of Gold(III)-Dithiocarbamato Complexes
Anti-Cancer Agents in Medicinal Chemistry Epidemiology and Management of Infectious Complications in Contemporary Management of Chronic Leukemias
Infectious Disorders - Drug Targets Emerging Roles for Modulation of microRNA Signatures in Cancer Chemoprevention
Current Cancer Drug Targets Hepatocellular Carcinoma Detection by Gallium Scan and Subsequent Treatment by Gallium Maltolate: Rationale and Case Study
Anti-Cancer Agents in Medicinal Chemistry Galectins: Major Signaling Modulators Inside and Outside the Cell
Current Molecular Medicine Prodrugs for Targeted Tumor Therapies: Recent Developments in ADEPT, GDEPT and PMT
Current Pharmaceutical Design The Proteasome in Health and Disease
Current Pharmaceutical Design Targeting Molecular Imaging of Breast Cancer by Radioimmunodetection Method in Nuclear Medicine
Current Molecular Imaging (Discontinued) Delivery of Intracellular-Acting Biologics in Pro-Apoptotic Therapies
Current Pharmaceutical Design Editorial (Hot Topic: MiRNAs as Legitimate Targets for Cancer Therapy)
Current Drug Targets Quantitative Analysis and Pharmacokinetics Study of Integrin Antagonist AP25 in Rat Plasma
Protein & Peptide Letters Leukocyte Traffic Blockade as a Therapeutic Strategy in Inflammatory Bowel Disease
Current Drug Targets A Targeted Therapy for Protein and Lipid Kinases in Chronic Lymphocytic Leukemia
Current Medicinal Chemistry Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling
Current Drug Targets MicroRNAs and Physical Activity
MicroRNA Pituitary Adenylate Cyclase-Activating Polypeptide: Focus on Structure- Activity Relationships of a Neuroprotective Peptide
Current Medicinal Chemistry ImmunoPET in Neoplasms of Gastrointestinal Tract, Liver and Pancreas in the XXIst Century: Bridging the Gap Between Diagnosis and Therapy
Reviews on Recent Clinical Trials Potential Interactions between miRNAs and Hypoxia: A New Layer in Cancer Hypoxia
Anti-Cancer Agents in Medicinal Chemistry